Chen Cheng-Hao Jacky, Jiang Henry, Martin Owen, Wilson-Smith Ashley R
The Collaborative Research (CORE) Group, Sydney, Australia.
Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
Ann Cardiothorac Surg. 2022 Jul;11(4):351-362. doi: 10.21037/acs-2022-bav-22.
Currently, bicuspid aortic valve (BAV) anatomy remains a relative contraindication for transcatheter aortic valve replacement (TAVR) due to concerns of suboptimal anatomy. However, recent advancements in the field have provided a wealth of promising data and more clinicians are opting for TAVR as an alternative to surgical repair. We aim to review and analyze the available data for TAVR in BAV patients, targeting procedural outcomes, clinical outcomes and mortality with up to two years of follow-up.
A literature search of five databases was performed and all primary studies published between 2002 and 2021 that reported procedural, clinical or mortality outcome data were identified. Following data extraction, a meta-analysis of means or proportions was performed using a random effects model. Heterogeneity was assessed using the I statistic.
A total of 22 studies with 1,945 BAV patients were identified. The mean age was 74.1 years and 58.8% of patients were male. Device success rates was 87.5%. Moderate to severe paravalvular leak (PVL) was seen in 3.7% of procedures. Clinical outcomes included new permanent pacemaker insertion (PPI) (11.8%), major bleeding (3.5%), major vascular complications (2.5%), stroke (2.3%), acute kidney injury (2.1%) and coronary obstruction (0.1%). Mortality in hospital, at 30-days, one and two years of follow-up were 1.9%, 2.1%, 9.6% and 12.9%, respectively.
This assessment of the available data on TAVR for BAV shows promising outcomes and low rates of complications. However, further research is warranted to reduce the heterogeneity of the available data and provide insight into outcomes beyond two years of follow-up.
目前,由于担心解剖结构不理想,二叶式主动脉瓣(BAV)解剖结构仍然是经导管主动脉瓣置换术(TAVR)的相对禁忌证。然而,该领域最近的进展提供了大量有前景的数据,越来越多的临床医生选择TAVR作为手术修复的替代方案。我们旨在回顾和分析BAV患者TAVR的现有数据,关注手术结局、临床结局以及长达两年随访期的死亡率。
对五个数据库进行文献检索,确定2002年至2021年期间发表的所有报告手术、临床或死亡率结局数据的原始研究。在数据提取之后,使用随机效应模型对均值或比例进行荟萃分析。使用I统计量评估异质性。
共确定了22项研究,涉及1945例BAV患者。平均年龄为74.1岁,58.8%的患者为男性。器械成功率为87.5%。3.7%的手术出现中至重度瓣周漏(PVL)。临床结局包括新的永久性起搏器植入(PPI)(11.8%)、大出血(3.5%)、严重血管并发症(2.5%)、中风(2.3%)、急性肾损伤(2.1%)和冠状动脉阻塞(0.1%)。住院死亡率、30天、1年和2年随访时的死亡率分别为1.9%、2.1%、9.6%和12.9%。
对BAV患者TAVR现有数据的这项评估显示出有前景的结局和较低的并发症发生率。然而,有必要进行进一步研究以减少现有数据的异质性,并深入了解两年以上随访期的结局。